X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support Coya Therapeutics to advance the clinical development of COYA 301 for treating patients suffering from Alzheimer's Disease and Amyotrophic Lateral Sclerosis.
Lead Product(s): COYA 301
Therapeutic Area: Neurology Product Name: COYA 301
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Houston Methodist Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2024
Details:
COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism, which is being evaluated for treating alzheimer disease.
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Details:
The financing will accelerate the development of COYA 302, Coya’s lead therapeutic candidate, is being evaluated in multiple neurodegenerative diseases, including FTD.
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alzheimer’s Drug Discovery Foundation
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 20, 2024
Details:
The license agreement covers the combination of COYA 301 with GM-CSF and additional immune analogues and provides a next generation approach with a novel combination to synergistically modulate and reduce inflammation.
Lead Product(s): COYA 301,GM-CSF
Therapeutic Area: Immunology Product Name: COYA 301
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: UNeMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 13, 2024
Details:
COYA 302 is a dual-mechanism investigational biologic combination immunotherapy comprised of proprietary low dose IL-2 and fusion protein CTLA-4 Ig. It is being evaluated for the treatment of frontotemporal dementia and parkinson’s disease.
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
COYA 302 is a dual-mechanism investigational biologic combination therapy comprised of proprietary low dose IL-2 and fusion protein CTLA-4 Ig. It is being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Lead Product(s): COYA 302
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The net proceeds will be used to support preclinical, clinical, and regulatory activities related to the company’s existing and future product candidate pipeline including COYA-201 which is under preclinical development for autoimmune, metabolic, neurodegenerative disorders.
Lead Product(s): COYA-201
Therapeutic Area: Immunology Product Name: COYA-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BTIG, LLC
Deal Size: $26.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 12, 2023
Details:
Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Interleukin 2,Abatacept
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
COYA 301 is a treg-enhancing biologic therapy, which will be supplied in a pre-filled syringe for subcutaneous injection, which is investigated for the treatment of alzheimer’s disease.
Lead Product(s): Coya 301
Therapeutic Area: Neurology Product Name: Coya 301
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
COYA 302 is a combination of COYA 301 (low dose IL-2) and CTLA4-Ig fusion protein. It is intended to enhance Treg function in vivo and downregulate the function of T effector cells, proinflammatory cells and lipid peroxides for treating ameliorate disease progression.
Lead Product(s): Coya 302
Therapeutic Area: Neurology Product Name: Coya 302
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
